About Humedics
Humedics is a company based in Berlin (Germany) founded in 2009 was acquired by Advanced Biological Laboratories in January 2023. Humedics has raised $8.52 million across 4 funding rounds from investors including KfW, Vesalius Biocapital Partners and Freie Universitat Berlin. The company has 11 employees as of December 31, 2020. Humedics offers products and services including LiMAx Test. Humedics operates in a competitive market with competitors including Sequana Medical, Xlumena, Salient Surgical Technologies, Autem Therapeutics and Yaqrit, among others.
- Headquarter Berlin, Germany
- Employees 11 as on 31 Dec, 2020
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Humedics Gmbh
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$8.52 M (USD)
in 4 rounds
-
Latest Funding Round
$7.85 M (USD), Series C
Nov 10, 2014
-
Investors
KfW
& 10 more
-
Employee Count
11
as on Dec 31, 2020
-
Acquired by
Advanced Biological Laboratories
(Jan 11, 2023)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Humedics
Humedics offers a comprehensive portfolio of products and services, including LiMAx Test.
Non-invasive method for analyzing liver capacity in clinical settings.
Funding Insights of Humedics
Humedics has successfully raised a total of $8.52M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $7.85 million completed in November 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Humedics
Humedics has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include KfW, Vesalius Biocapital Partners and Freie Universitat Berlin.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life sciences-focused VC firm investing in Europe and Canada
|
Locked | Locked | Locked | |
|
Tech & Life Sciences focused stage agnostic VC firm investing in Europe, Asia & the US
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked |
Investor details for Humedics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Humedics
Investment portfolio details for Humedics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Humedics
Detailed financials for Humedics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Humedics Comparisons
Peer comparison for Humedics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Humedics
Humedics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sequana Medical, Xlumena, Salient Surgical Technologies, Autem Therapeutics and Yaqrit, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Implantable battery-powered pumps for ascites removal are developed.
|
|
| Locked | Locked | Locked |
Image-guided therapeutic endoscopy devices are developed for medical procedures.
|
|
| Locked | Locked | Locked |
Electrosurgical systems for surgical resections and procedures are developed.
|
|
| Locked | Locked | Locked |
Bioelectric platforms for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Liver dialysis devices for treating cirrhosis and failure are developed.
|
Detailed competitors of Humedics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Humedics
Complete news archive for Humedics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Humedics
Humedics was founded in 2009.
Humedics is headquartered in Berlin, Germany. It is registered at Berlin, Berlin, Germany.
Humedics is a funded company, having raised a total of $8.52M across 4 funding rounds to date.
As of Dec 31, 2020, the latest employee count at Humedics is 11.
Founded in 2009 and based in Berlin, Germany, Humedics operates in the medical diagnostics sector. Breath-based assays for evaluating liver function are developed, with the LiMax product focusing on CYP1A2 enzyme activity. C13 methacetin is administered and metabolized into detectable C-13 carbon dioxide in exhaled breath, using an ultrasensitive FLIP system in a test mask. Early-stage liver disease is identified for applications in surgery, transplantation, hepatology, and oncology.
Humedics's top competitors include Sequana Medical, Yaqrit and CalmiGo.
Humedics offers LiMAx Test.
Humedics has 11 investors. Key investors include KfW, Vesalius Biocapital Partners, Freie Universitat Berlin, Advanced Biological Laboratories, and Seventure Partners.